Nuvation Bio Inc: 91% of patients with advanced Ros1-positive non-small cell lung cancer treated with talentinib had tumor atrophy. These patients were Ros1 Tki-Naíve
Nuvation Bio Inc：在接受他乐替尼治疗的晚期 Ros1 阳性非小细胞肺癌患者中有 91% 的患者肿瘤萎缩这些患者是 Ros1 Tki-Naíve
Nuvation Bio Inc: 91% of patients with advanced Ros1-positive non-small cell lung cancer treated with talentinib had tumor atrophy. These patients were Ros1 Tki-Naíve
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.